Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Viread

Viread 245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 140–141

HOS-110808 · Präparat HOS-093385

140  Medicinal product by Effects on drug levels Recommendation therapeutic areas Mean percent change in AUC, Cmax, concerning (dose in mg) Cmin co-administration with 245 mg tenofovir disoproxil Sofosbuvir/Velpatasvir/ Sofosbuvir: Increased plasma Voxilaprevir (400 mg/100 mg/ AUC: ↔ concentrations of tenofovir 100 mg+100 mg q.d.)3 + Cmax: ↓ 30% resulting from co- Darunavir (800 mg q.d.) + Cmin: N/A administration of tenofovir Ritonavir (100 mg q.d.) + disoproxil, Emtricitabine/Tenofovir GS-3310072: sofosbuvir/velpatasvir/voxilap disoproxil (200 mg/245 mg q.d.) AUC: ↔ revir and darunavir/ritonavir Cmax:↔ may increase adverse Cmin: N/A reactions related to tenofovir disoproxil, including renal Velpatasvir: disorders. AUC: ↔ The safety of tenofovir Cmax: ↔ disoproxil when used with Cmin: ↔ sofosbuvir/velpatasvir/voxilap revir and a pharmacokinetic Voxilaprevir: enhancer (e.g. ritonavir or AUC: ↑ 143% cobicistat) has not been Cmax:↑ 72% established. Cmin: ↑ 300% The combination should be Darunavir: used with caution with AUC: ↔ frequent renal monitoring (see Cmax: ↔ section 4.4). Cmin: ↓ 34%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) cobicistat (HOS-088111) voxilaprevir (HOS-108930) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)